Search
for
Sort by
Research 511–540 of 1000+
- Involucrin, but not filaggrin and Kdap mRNA, expression is downregulated in 3-D cultures of intact rat hair bulbs after calcium stimulation
- 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
- Most men choose eyebrows versus scalp hair: Response to Mostaghimi et al., “Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the phase 3 THRIVE-AA2 trial of deuruxolitinib in adult patients with alopecia areata”
- Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- 74643 Deuruxolitinib improves scalp hair regrowth over time in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- 75810 Long-term efficacy, complete scalp hair regrowth, and normal body hair and nails in patients with alopecia areata (AA) receiving ritlecitinib 50 mg once daily up to 3 years in the ALLEGRO clinical trial program
- 75893 Long-term efficacy, complete scalp hair regrowth and normal body hair/nails in adolescents with severe alopecia areata (AA) receiving ritlecitinib up to 3 years in the ALLEGRO clinical trials
- 74582 Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
- Pengaruh Ekstrak Metanol Batang Etlingera alba (Blume) A. D. Poulsen Terhadap Penekanan Genicaspase-3 sebagai Penanda Apoptosis pada Lini Sel Kanker Payudara T47D Secara In Vitro
- 125: Individual Severity of Alopecia Tool (SALT) score trajectories of roll-over adolescent patients with alopecia areata (AA) treated with ritlecitinib in the ongoing long-term, open-label, phase 3 ALLEGRO-LT study
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- Faculty Opinions recommendation of Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor blinded, 3-arm, pilot trial.
- Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor blinded, 3‐arm, pilot trial
- 42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)
- Referee report. For: Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment [version 3; peer review: 2 approved]
- 금잔화, 상황, 어성초 에탄올 추출물의 세포독성 평가 및 3T3-L1 세포에 대한 육모 효과
- Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
- Referee report. For: Advances in Understanding Hair Growth [version 1; referees: 3 approved]
- Referee report. For: Advances in Understanding Hair Growth [version 1; referees: 3 approved]
- Safety and efficacy of tavaborole (AN2690), a novel boron-based molecule, in 3 phase II trials for the topical treatment of toenail onychomycosis
- 24. 力発揮および操作性からみた下肢運動の一側優位性(神経・感覚,一般口演,第63回日本体力医学会大会)
- 1. 2年間の低負荷レジスタンストレーニングが高齢者の筋機能に及ぼす効果(第134回日本体力医学会関東地方会)
- A randomized, blinded, three-arm, multicenter trial comparing the efficacy and safety of fluconazole given once daily for 3 or 6 weeks with griseofulvin given once daily for 6 weeks in pediatric patients with tinea capitis
- From the Literature<i>J Investig Dermatol</i>, Symp Proc 1999 December; for (3); 2~2-4; Authors: Whiting DA et alREVIEW: Ahmet Seyhan, MD, Levent Yoleri, MD, Ali Barutcu, MD: Immediate hair transplantation into a newly closed wound to conceal the final scar on the hair-bearing skin. <i>Plast Reconstr Surg</i>, 105:5, 1866-1870, 2000.REVIEW: Handbook of Diseases of the Hair and Scalp. By Rodney Sinclair, Cedrick Banfield and Rodney Dawber; 233 Pages. Published by Blackwell Science 1999.
- An isolated, implausibly large effect in a case-control study of digit ratio (2D:4D) and male androgenetic alopecia: Comment on Unal (J Cosmet Dermatol 2018;17(3):545-548)
- Thorat Kulloli, K., & Kulloli, V. (2026). The Effect of Anu Taila Nasya with Shiro Abhyanga and Iron Supplementation in the Management of Khalitya (Hair Loss): An Ayurvedic Single Case Report. International Journal of Diagnostics And Research, 3(3), 26–34. https://doi.org/10.5281/zenodo.19595900
- Thorat Kulloli, K., & Kulloli, V. (2026). The Effect of Anu Taila Nasya with Shiro Abhyanga and Iron Supplementation in the Management of Khalitya (Hair Loss): An Ayurvedic Single Case Report. International Journal of Diagnostics And Research, 3(3), 26–34. https://doi.org/10.5281/zenodo.19595900
- Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3‐month, controlled, assessor‐blinded study